Literature DB >> 16287062

Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival.

Sara Ek1, Erik Björck, Carl-Magnus Högerkorp, Magnus Nordenskjöld, Anna Porwit-MacDonald, Carl A K Borrebaeck.   

Abstract

We have analyzed mantle cell lymphomas (MCLs), using high-density DNA microarrays, and confirmed the expression of differentially regulated antigens, using flow cytometry and immunohistochemistry. The results show that MCLs acquire expression of molecules that normally are involved in interaction with other immune cells and, thus, might affect the ability of the tumor to survive. The MCL signature is represented by the overexpression of the chemokine CCL4 (MIP-1beta), implicated in the recruitment of regulatory T cells, as well as CCL5 and 4-1BB-L. The latter molecules are normally involved in chemotaxis of T cells and B cell activation, respectively. Signaling through 4-1BB-L allows B cells to proliferate and the expression of its ligand, by the intra-tumoral mesh of follicular dendritic cells (FDC), could thus serve as a paracrine loop facilitating growth and survival of MCL cells. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16287062     DOI: 10.1002/ijc.21579

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

2.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

3.  Association of chemokine CCL5 and systemic malignancies.

Authors:  Shailendra Kapoor
Journal:  J Hum Genet       Date:  2008-03-27       Impact factor: 3.172

4.  Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.

Authors:  Kai Song; Brett H Herzog; Minjia Sheng; Jianxin Fu; J Michael McDaniel; Hong Chen; Jia Ruan; Lijun Xia
Journal:  Cancer Res       Date:  2013-10-24       Impact factor: 12.701

5.  SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies.

Authors:  Elin Gustavsson; Sandra Sernbo; Elin Andersson; Donal J Brennan; Michael Dictor; Mats Jerkeman; Carl Ak Borrebaeck; Sara Ek
Journal:  Mol Cancer       Date:  2010-07-12       Impact factor: 27.401

Review 6.  CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

Authors:  Dandan Lv; Yan Zhang; Ha-Jeong Kim; Lixing Zhang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2013-02-04       Impact factor: 11.530

7.  Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Authors:  Betty Y Chang; Michelle Francesco; Martin F M De Rooij; Padmaja Magadala; Susanne M Steggerda; Min Mei Huang; Annemieke Kuil; Sarah E M Herman; Stella Chang; Steven T Pals; Wyndham Wilson; Adrian Wiestner; Marcel Spaargaren; Joseph J Buggy; Laurence Elias
Journal:  Blood       Date:  2013-08-12       Impact factor: 22.113

8.  Chemokine polymorphisms and lymphoma: a pooled analysis.

Authors:  Paige M Bracci; Christine F Skibola; Lucia Conde; Eran Halperin; Tracy Lightfoot; Alex Smith; Randi A Paynter; Danica R Skibola; Luz Agana; Eve Roman; Eleanor Kane; John K Wiencke
Journal:  Leuk Lymphoma       Date:  2010-03

9.  Atypical chemokine receptor D6 inhibits human non-small cell lung cancer growth by sequestration of chemokines.

Authors:  Feng Ying Wu; Jiang Fan; Liang Tang; Yin Min Zhao; Cai Cun Zhou
Journal:  Oncol Lett       Date:  2013-05-21       Impact factor: 2.967

10.  Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.

Authors:  J Panse; K Friedrichs; A Marx; Y Hildebrandt; T Luetkens; K Barrels; C Horn; T Stahl; Y Cao; K Milde-Langosch; A Niendorf; N Kröger; S Wenzel; R Leuwer; C Bokemeyer; S Hegewisch-Becker; D Atanackovic
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.